Repatha reduced the risk of heart attack by 27%, the risk of stroke by 21% and the risk of coronary revascularization by 22%.
ORBITA was a double-blind, randomized controlled trial that evaluated PCI vs. a placebo procedure for improved exercise capacity in patients with severe coronary disease who were receiving optimum medical therapy.
On multivariable regression models, depression was a significant independent predictor of 30-day chest pain recurrence after adjustment.
They found that patients who only took the ACE inhibitor, or an angiotensin receptor blocker, and statin were no more likely to die than those who took all 3 prescribed treatments.
Clinical data from the Turbulence study (n=1,807) showed CADence had comparable performance to a SPECT nuclear stress test in excluding obstructive CAD in patients with chest pain and risk factors.
The products were distributed to healthcare facilities nationwide between March 9 and June 1 and have expiration dates ranging from June 6 to August 15, 2017.
XC001 is an investigational cardiovascular angiogenic gene therapy that promotes angiogenesis to provide arterial blood flow to myocardial regions with inadequate blood supply.
The data showed patients treated with metoprolol during acute myocardial infarction had a 40% reduced extent of microvascular obstruction.
An online tool can accurately predict which patients with chest pain are likely to have normal non-invasive test results and remain free of cardiac adverse events.
Angionetics has announced that its Phase 3 clinical investigation of Generx (Ad5FGF-4) has been granted Fast Track status by the Food and Drug Administration (FDA).
Espero announced the launch of GoNitro (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.
Aralez announced that the Food and Drug Administration (FDA) has approved Yosprala (omeprazole and aspirin) to treat patients who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events and who are at risk of developing aspirin-associated gastric ulcers.
Espero announced that the Food and Drug Administration (FDA) has approved GoNitro (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.
Mylan announced the launch of Metoprolol Tartrate Tablets in new 37.5mg and 75mg strengths, the generic version of Novartis' Lopressor.
Adding ranolazine in patients with type 2 diabetes treated with glimepiride, but not metformin, significantly lowered HbA1c over 24 weeks, according to a study published in Diabetes, Obesity, and Metabolism.
The FDA has accepted for review the New Drug Application (NDA) for GoNitro (nitroglycerin; Espero) for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.
Smoking cessation after acute myocardial infarction (AMI) reduces angina and boosts mental health and quality of life.
The FDA has accepted for filing the New Drug Application (NDA) for ready-to-use (RTU) bivalirudin (Eagle) for the treatment of patients undergoing percutaneous coronary intervention (PCI) with use of glycoprotein IIb/IIa inhibitor; undergoing PCI with, or at risk of heparin-induced thrombocytopenia and thrombosis syndrome; or with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).